PMID- 26597814
OWN - NLM
STAT- MEDLINE
DCOM- 20161014
LR  - 20221207
IS  - 2211-3436 (Electronic)
IS  - 2211-3428 (Linking)
VI  - 39
IP  - 1
DP  - 2016 Feb
TI  - Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center 
      (MSKCC) risk classification and bone metastasis in Chinese patients with 
      metastatic renal cell carcinoma.
PG  - 15-21
LID - 10.1007/s13402-015-0245-5 [doi]
AB  - PURPOSE: Several prognostic models have been developed to assess the efficacy and 
      safety of sorafenib for metastatic renal cell carcinoma (mRCC), but few studies 
      have validated its use in Chinese patients. The objective of this single center, 
      single arm retrospective study was to examine the efficacy and safety of 
      sorafenib and its related prognostic clinico-pathologic factors in Chinese mRCC 
      patients. METHODS: One hundred thirty four mRCC patients were enrolled. All 
      patients received 400 mg of sorafenib orally twice daily. The dose was 
      subsequently adjusted in the event of treatment-induced toxicity. Tumor response, 
      progression-free survival (PFS), overall survival (OS) and adverse events (AEs) 
      were determined. RESULTS: The median PFS and OS were 10 months (1-36 months) and 
      22 months (2-37 months), respectively. Complete, partial, and stable disease were 
      observed in two (1.49%), 24 (17.91%), and 99 (73.88%) patients, respectively. 
      Hand/foot skin reactions, diarrhea and fatigue were the most commonly observed 
      AEs following sorafenib treatment. Among the AEs, only 13 grades 3 and 4 were 
      observed. Multivariate analysis revealed that independent predictive factors for 
      PFS included Eastern Cooperative Oncology Group (ECOG) status, Memorial 
      Sloan-Kettering Cancer Center (MSKCC) risk status, and bone metastasis (all 
      p < 0.05). Factors associated with OS included MSKCC risk values, bone metastasis 
      and sorafenib-induced hypertension (all p < 0.05). CONCLUSION: The introduction 
      of sorafenib therapy for mRCC in Chinese patients may lead to a favorable disease 
      control with acceptable tolerability. In addition, the parameters predicting 
      favorable outcomes, including ECOG status, MSKCC risk status and bone metastasis, 
      may have prognostic value in clinical practice.
FAU - Zhang, Yushi
AU  - Zhang Y
AD  - Department of Urology, Peking Union Medical College Hospital, Chinese Academy of 
      Medical Sciences, Shuaifuyuan Dongdan, Dongcheng District, Beijing, 100730, 
      China.
FAU - Li, Yongqiang
AU  - Li Y
AD  - Department of Urology, Peking Union Medical College Hospital, Chinese Academy of 
      Medical Sciences, Shuaifuyuan Dongdan, Dongcheng District, Beijing, 100730, 
      China.
FAU - Cai, Yi
AU  - Cai Y
AD  - Department of Urology, Peking Union Medical College Hospital, Chinese Academy of 
      Medical Sciences, Shuaifuyuan Dongdan, Dongcheng District, Beijing, 100730, 
      China.
FAU - Wang, Ke
AU  - Wang K
AD  - Department of Epidemiology, Institute of Basic Medicine, Chinese Academy of 
      Medical Sciences, Shuaifuyuan Dongdan, Dongcheng District, Beijing, 100730, 
      China.
FAU - Li, Hanzhong
AU  - Li H
AD  - Department of Urology, Peking Union Medical College Hospital, Chinese Academy of 
      Medical Sciences, Shuaifuyuan Dongdan, Dongcheng District, Beijing, 100730, 
      China. Lihz12@yeah.net.
LA  - eng
PT  - Journal Article
DEP - 20151123
PL  - Netherlands
TA  - Cell Oncol (Dordr)
JT  - Cellular oncology (Dordrecht)
JID - 101552938
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Asian People
MH  - Bone Neoplasms/drug therapy/*secondary
MH  - Carcinoma, Renal Cell/*drug therapy/*pathology
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/*pathology
MH  - Male
MH  - Middle Aged
MH  - Niacinamide/adverse effects/*analogs & derivatives/therapeutic use
MH  - Phenylurea Compounds/adverse effects/*therapeutic use
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - Sorafenib
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Chinese
OT  - Metastatic renal cell carcinoma
OT  - Prognostic factors
OT  - Safety
OT  - Sorafenib
EDAT- 2015/11/26 06:00
MHDA- 2016/10/16 06:00
CRDT- 2015/11/25 06:00
PHST- 2015/09/14 00:00 [accepted]
PHST- 2015/11/25 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2016/10/16 06:00 [medline]
AID - 10.1007/s13402-015-0245-5 [pii]
AID - 10.1007/s13402-015-0245-5 [doi]
PST - ppublish
SO  - Cell Oncol (Dordr). 2016 Feb;39(1):15-21. doi: 10.1007/s13402-015-0245-5. Epub 
      2015 Nov 23.